Switch theme
Sign up to access all valuation multiples
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
2016
40
LTM Revenue $76.0M
LTM EBITDA $39.1M
$96.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OSE Immunotherapeutics has a last 12-month revenue of $76.0M and a last 12-month EBITDA of $39.1M.
In the most recent fiscal year, OSE Immunotherapeutics achieved revenue of $2.4M and an EBITDA of -$18.8M.
OSE Immunotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OSE Immunotherapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $19.7M | $2.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$14.1M | -$18.8M | XXX | XXX | XXX |
| EBITDA Margin | -72% | -786% | XXX | XXX | XXX |
| Net Profit | -$18.1M | -$19.1M | XXX | XXX | XXX |
| Net Margin | -92% | -797% | XXX | XXX | XXX |
| Net Debt | n/a | $15.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, OSE Immunotherapeutics's stock price is EUR 6 (or $6).
OSE Immunotherapeutics has current market cap of EUR 122M (or $131M), and EV of EUR 89.9M (or $96.6M).
See OSE Immunotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $96.6M | $131M | XXX | XXX | XXX | XXX | $1.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, OSE Immunotherapeutics has market cap of $131M and EV of $96.6M.
OSE Immunotherapeutics's trades at 1.3x LTM EV/Revenue multiple, and 2.5x LTM EBITDA.
Analysts estimate OSE Immunotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for OSE Immunotherapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $96.6M | XXX | XXX | XXX |
| EV/Revenue | 40.4x | XXX | XXX | XXX |
| EV/EBITDA | -5.1x | XXX | XXX | XXX |
| P/E | -5.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOSE Immunotherapeutics's NTM/LTM revenue growth is -43%
OSE Immunotherapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, OSE Immunotherapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate OSE Immunotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for OSE Immunotherapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -88% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -786% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -829% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 770% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1135% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OSE Immunotherapeutics acquired XXX companies to date.
Last acquisition by OSE Immunotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . OSE Immunotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was OSE Immunotherapeutics founded? | OSE Immunotherapeutics was founded in 2016. |
| Where is OSE Immunotherapeutics headquartered? | OSE Immunotherapeutics is headquartered in France. |
| How many employees does OSE Immunotherapeutics have? | As of today, OSE Immunotherapeutics has 40 employees. |
| Who is the CEO of OSE Immunotherapeutics? | OSE Immunotherapeutics's CEO is Mr. Nicolas Poirier, PhD. |
| Is OSE Immunotherapeutics publicy listed? | Yes, OSE Immunotherapeutics is a public company listed on PAR. |
| What is the stock symbol of OSE Immunotherapeutics? | OSE Immunotherapeutics trades under OSE ticker. |
| When did OSE Immunotherapeutics go public? | OSE Immunotherapeutics went public in 2015. |
| Who are competitors of OSE Immunotherapeutics? | Similar companies to OSE Immunotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OSE Immunotherapeutics? | OSE Immunotherapeutics's current market cap is $131M |
| What is the current revenue of OSE Immunotherapeutics? | OSE Immunotherapeutics's last 12-month revenue is $76.0M. |
| What is the current EBITDA of OSE Immunotherapeutics? | OSE Immunotherapeutics's last 12-month EBITDA is $39.1M. |
| What is the current EV/Revenue multiple of OSE Immunotherapeutics? | Current revenue multiple of OSE Immunotherapeutics is 1.3x. |
| What is the current EV/EBITDA multiple of OSE Immunotherapeutics? | Current EBITDA multiple of OSE Immunotherapeutics is 2.5x. |
| What is the current revenue growth of OSE Immunotherapeutics? | OSE Immunotherapeutics revenue growth between 2023 and 2024 was -88%. |
| Is OSE Immunotherapeutics profitable? | Yes, OSE Immunotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
